Home Cart Sign in  
Chemical Structure| 1339928-25-4 Chemical Structure| 1339928-25-4

Structure of Fimepinostat
CAS No.: 1339928-25-4

Chemical Structure| 1339928-25-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively.

Synonyms: CUDC-907

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fimepinostat

CAS No. :1339928-25-4
Formula : C23H24N8O4S
M.W : 508.55
SMILES Code : O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO
Synonyms :
CUDC-907
MDL No. :MFCD22420823
InChI Key :JOWXJLIFIIOYMS-UHFFFAOYSA-N
Pubchem ID :54575456

Safety of Fimepinostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Fimepinostat

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • p110β

    PI3Kβ, IC50:54 nM

  • p110α

    PI3Kα, IC50:19 nM

  • p110δ

    PI3Kδ, IC50:39 nM

  • HDAC10

    HDAC10, IC50:2.8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
NCI-H82 5.93 nM To determine the LD50 dose of Fimepinostat PMC10131464
NCI-H209 23.45 nM To determine the LD50 dose of Fimepinostat PMC10131464
HuH-7 cells 10 µM 3 days Screened out CUDC-907 as a potential anti-HCC agent with inhibition ratios above 85% PMC8585736
J-lat Tat-GFP cells 25 nM 48 hours Fimepinostat showed a similar latency-reversing effect to romidepsin in J-lat Tat-GFP cells without significantly affecting cell viability. PMC6816120
ACH-2 cells 50 nM 48 hours Fimepinostat induced HIV-1 p24 production in ACH-2 cells, with a trend towards higher production compared to panobinostat. PMC6816120
NGP 1.94 µM 72 hours CUDC-907 significantly inhibits NB cell proliferation PMC8870466
LAN-5 0.91 µM 72 hours CUDC-907 significantly inhibits NB cell proliferation PMC8870466

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice RPM mouse model oral 0.5 mg Two subsequent days every two weeks for two weeks To evaluate the therapeutic effect of Fimepinostat on SCLC in vivo PMC10131464
Balb/c nude mice SMMC-7721 xenograft model oral 15 mg/kg 5 days per week for 3 weeks CUDC-907 significantly suppressed tumor growth in the xenograft HCC model PMC8585736

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03002623 Thyroid Neoplasms|Poorly Diffe... More >>rentiated and Undifferentiated Thyroid Cancer|Differentiated Thyroid Cancer Less << PHASE2 TERMINATED 2018-02-12 National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT05971758 Cushing Disease PHASE2 NOT_YET_RECRUITING 2025-01-25 -
NCT02674750 Relapsed and/or Refractory Dif... More >>fuse Large B-cell Lymphoma Including With Myc Alterations Less << PHASE2 COMPLETED 2019-05-28 University of California San F... More >>rancisco-Fresno, Fresno, California, 93701, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|University of Chicago, Chicago, Illinois, 60647, United States|Norton Cancer Institute, Louisville, Kentucky, 40207, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|University of Rochester, Rochester, New York, 55905, United States|University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, 73104, United States|Cancer Care Associates, Tulsa, Oklahoma, 74104, United States|Penn State Hershey Cancer Institute-Clinical Trials Office, Hershey, Pennsylvania, 17033, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|University of Tennessee Cancer Center, Knoxville, Tennessee, 37920, United States|Tennessee Oncology Sarah Cannon, Nashville, Tennessee, 37203, United States|Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Houston Methodist Hospital, Houston, Texas, 77030, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Durán i Reynals, Servicio de Oncología, Barcelona, 08908, Spain|Hospital Universitario Puerta de Hierro, Madrid, 28220, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain Less <<
NCT02909777 Lymphoma|Neuroblastoma|Brain T... More >>umor|Solid Tumor Less << PHASE1 ACTIVE_NOT_RECRUITING 2025-01-25 University of California, San ... More >>Francisco, Benioff Children's Hospital, San Francisco, California, 94158, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|Texas Children's, Baylor College of Medicine, Houston, Texas, 77030, United States Less <<
NCT02307240 Triple-Negative Breast Cancer|... More >>High-grade Serous Ovarian Cancer|Solid Tumors|NUT Midline Carcinoma Less << PHASE1 COMPLETED 2019-05-31 UCSF School of Medicine, San F... More >>rancisco, California, 94143, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.83mL

1.97mL

0.98mL

19.66mL

3.93mL

1.97mL

References

 

Historical Records

Categories